Norponin® XO

7 trials with experimentally induced coccidiosis were performed between 2016 and 2019: 2 in Europe (Belgium, Spain), 4 in America (3 in the USA, 1 in Peru) and one in Asia (Vietnam).

Each trial was conducted with an infected untreated control group (IUC, negative control), an infected group treated with coccidiostats (Crtl+, positive control), and an infected group with Norponin® XO supplementation.

With Norponin® XO supplementation, a significant reduction in intestinal lesions due to Eimeria acervulina (-25%), Eimeria maxima (-29%) and a numerical reduction in intestinal lesions due to Eimeria tenella (-20%) were observed (measured by the Johnson & Reid scale). In addition, an improvement in feed conversion rate, as well as an increase in average daily weight gain were observed. Due to a reduced mortality rate (data not shown), the increased performance parameters resulted in a significant improvement of the European Broiler Index (+7%, EBI) compared to the negative control. In addition, no significant difference was observed between birds receiving coccidiostats and birds supplemented with Norponin® XO.

Figure 1: Incidence of intestinal lesions caused by E.acervulina, E.maxima, and E.tenella in the negative control group (IUC, infected untreated control), the positive control group (Ctrl+, infected and treated with coccidiostats), and the infected group with Norponin® XO supplementation (Norponin® XO), scored using the Johnson&Reid scoring index (Johnson and Reid, 1970).

Figure 2: Collected performance parameters ADG (Average Daily Gain), FCR (Feed conversion ratio) and EBI (European Broiler Index, EBI= (ADG x Livability)/ (10 x FCR)).